Lifeward (LFWD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Sep, 2026Executive summary
The annual and extraordinary general meeting is scheduled for October 30, 2026, with in-person attendance planned and remote options if needed.
The Board recommends voting in favor of all proposals, including director elections, compensation matters, and auditor re-appointment.
Shareholders of record as of September 30, 2026, are eligible to vote, with detailed proxy and voting instructions provided.
Voting matters and shareholder proposals
Proposals include re-election of Class III directors, election of an external director, approval of director and CEO compensation, issuance of shares above Nasdaq exchange cap, renewal of compensation policy, auditor re-appointment, say-on-pay, and advisory vote on say-on-pay frequency.
Board recommends voting "FOR" Proposals 1-8 and "EVERY YEAR" for Proposal 9.
Special Majority is required for certain proposals under Israeli law, particularly those involving compensation and external director election.
Shareholder proposals for the 2027 AGM must be submitted by May 28, 2027, with additional requirements for director nominations.
Board of directors and corporate governance
Board currently has eight seats, six occupied; after the meeting, seven directors are expected to serve.
Board is divided into three classes, with Class III directors up for re-election until 2029.
Board leadership structure separates CEO and Chairman roles, with active risk oversight and committee structure for audit, compensation, and governance.
Director independence is assessed under Nasdaq and Israeli law; currently, four directors are independent.
Nominating committee considers diversity of experience and skills but has no formal diversity policy.
Latest events from Lifeward
- Shareholders will vote on director elections, compensation, share issuance, and auditor re-appointment.LFWD
Proxy filing - Scaling robotics and AI-powered rehab with strong reimbursement and global reach.LFWD
Investor presentation - Q2 2026 revenue up 16% to $6.6M; net loss widens; cash position improves but risks remain.LFWD
Q2 2026 - Registering 2,066,662 shares for resale, with proceeds possible only from warrant exercises.LFWD
Registration filing - Revenue dropped 22% to $3.9M; net loss widened, but cash rose to $11.4M.LFWD
Q1 2026 - Registering 7.26M shares for resale after acquisitions, with no proceeds to the company.LFWD
Registration filing - 2025 revenue fell 14%, but unit sales, gross margin, and efficiency improved amid strategic expansion.LFWD
Q4 2025 - Shareholders to vote on acquisition, major share issuances, and board changes, enabling new growth.LFWD
Proxy Filing - Q2 revenue soared 400%+ to $6.7M, with Medicare and AlterG fueling growth and narrowed losses.LFWD
Q2 2024